Track topics on Twitter Track topics that are important to you
Published on BioPortfolio: 2018-02-21T19:15:11-0500
To evaluate the safety of IV Lacosamide in children with partial-onset epilepsy, ages 4-35 years old, inclusive, who are either unable to take oral medication or require intravenous admini...
Currently, treatment with a specific anti-epileptic drug mainly depends on the physicians' preference, as there are no studiessupporting the use of one specific anticonvulsant in glioma pa...
The purpose of the trial is to evaluate the safety of iv lacosamide delivered in a single dose followed by 6,5 days of oral dosing with lacosamide in patients with partial-onset seizures.
The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.
The purpose of this trial is to evaluate the safety and pharmacokinetics of Lacosamide (LCM) syrup in children ages 2-17 with uncontrolled partial seizures when added to 1 to 3 other seizu...
To implement pharmacokinetic drug monitoring and individualize the posology of new antiepileptic drugs, the first HPLC-diode array detection method was developed and validated to simultaneously quanti...
Lacosamide is a new generation antiepileptic drug (AED) that is eliminated by both hepatic and renal mechanisms. Lacosamide elimination by Continuous Renal Replacement Therapy (CRRT) has never been st...
Over last fifty years, intravenous (iv) phenytoin (PHT) loading dose has been the treatment of choice for patients with benzodiazepine-resistant convulsive status epilepticus and several guidelines re...
Seizures constitute a determining aspect in quality of life and are frequently challenging in palliative care-a field where treatment has yet to be standardised. Levetiracetam-a new generation anticon...
Epilepsy is one of the most common chronic neurological diseases, and its pharmacological treatment holds great importance for both physicians and national authorities, especially considering the high...
A malignant BRAINSTEM neoplasm of the PONS. They are more commonly found in children than adults.
A BRAIN-specific hyalectin that may play a role in terminally differentiating NEURONS. It is found highly overexpressed in primary BRAIN TUMORS and in experimental models of GLIOMA.
Rare, slow-growing, benign intraventricular tumors, often asymptomatic and discovered incidentally. The tumors are classified histologically as ependymomas and demonstrate a proliferation of subependymal fibrillary astrocytes among the ependymal tumor cells. (From Clin Neurol Neurosurg 1997 Feb;99(1):17-22)
Neoplasms located in the brain ventricles, including the two lateral, the third, and the fourth ventricle. Ventricular tumors may be primary (e.g., CHOROID PLEXUS NEOPLASMS and GLIOMA, SUBEPENDYMAL), metastasize from distant organs, or occur as extensions of locally invasive tumors from adjacent brain structures.
Benign and malignant neoplasms that arise from the optic nerve or its sheath. OPTIC NERVE GLIOMA is the most common histologic type. Optic nerve neoplasms tend to cause unilateral visual loss and an afferent pupillary defect and may spread via neural pathways to the brain.